Oppenheimer analyst Andreas Argyrides lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $45.00 (from $123.00) while maintaining an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE